OVID short interest
Ovid Therapeutics Inc. · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 18,948,082 |
|---|---|
| Change vs prior report | -2,203,097 (-10.4%) |
| Change over six months | +102.9% |
| Days to cover | 8.93 (sector: 3.78) |
| Average daily volume | 2,122,356 |
| Rank in Healthcare | #149 of 922 by days to cover |
OVID short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 18,948,082 | -10.4% | 8.93 | 2,122,356 |
| 2026-09-15 | 21,151,179 | +2.3% | 17.25 | 1,226,403 |
| 2026-08-31 | 20,674,725 | -4.4% | 13.12 | 1,576,338 |
| 2026-08-14 | 21,636,407 | +0.8% | 15.18 | 1,425,283 |
| 2026-07-31 | 21,462,926 | -2.6% | 14.01 | 1,532,367 |
| 2026-07-15 | 22,039,852 | +0.2% | 12.65 | 1,741,963 |
| 2026-06-30 | 21,998,879 | +85.6% | 3.78 | 5,823,749 |
| 2026-06-15 | 11,855,450 | +11.5% | 6.71 | 1,767,484 |
| 2026-05-29 | 10,632,208 | +5.4% | 8.44 | 1,260,258 |
| 2026-05-15 | 10,091,554 | +18.4% | 4.57 | 2,205,900 |
| 2026-04-30 | 8,527,074 | +22.6% | 4.44 | 1,920,664 |
| 2026-04-15 | 6,957,013 | -25.5% | 1.70 | 4,102,471 |
| 2026-03-31 | 9,337,824 | +71.2% | 1.53 | 6,101,520 |
| 2026-03-13 | 5,454,309 | +7.1% | 2.10 | 2,596,521 |
| 2026-02-27 | 5,090,831 | -2.1% | 7.23 | 703,732 |
| 2026-02-13 | 5,201,016 | +7.4% | 3.64 | 1,427,237 |
| 2026-01-30 | 4,840,700 | +0.4% | 2.62 | 1,848,363 |
| 2026-01-15 | 4,820,308 | +9.9% | 3.50 | 1,378,337 |
| 2025-12-31 | 4,384,071 | +5.0% | 2.62 | 1,675,937 |
| 2025-12-15 | 4,174,573 | +8.1% | 2.69 | 1,554,152 |
| 2025-11-28 | 3,861,388 | +10.3% | 2.00 | 1,930,179 |
| 2025-11-14 | 3,499,202 | +1.0% | 2.65 | 1,318,270 |
| 2025-10-31 | 3,465,773 | -9.5% | 2.09 | 1,655,192 |
| 2025-10-15 | 3,830,348 | +463.3% | 1.00 | 7,847,599 |
| 2025-09-30 | 680,035 | +39.1% | 1.00 | 2,626,824 |
import finzdata as yf
yf.Ticker("OVID").short_interest # every report since 2017
yf.Client().short_interest(["OVID"], start="2018-01-01")Healthcare short interest · OVID price history · Who owns OVID · All short interest